A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phas...

Update Il y a 4 ans
Reference: EUCTR2007-005376-13

A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of this study is to compare the four therapy regimens with regard to efficacy failure rate.


Inclusion criteria

  • Prophylaxis of rejection in kidney allograft recipients (via immunosuppression)